KBC Group
TARS icon

KBC Group’s Tarsus Pharmaceuticals TARS Stock Holding History

KBC Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82K Hold
1,296
– – ﹤0.01% 1519
2026
Q1 		$91K Hold
1,296
– – ﹤0.01% 1379
2025
Q4 		$106K Hold
1,296
– – ﹤0.01% 1235
2025
Q3 		$77K Buy
+1,296
New +$63.8K ﹤0.01% 1431

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

KBC Group's TARS Position: Q2 2026 in Review

KBC Group held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 1,296 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #1519.

KBC Group first reported a position in TARS in Q3 2025 and has held it in 4 quarters since. The position peaked at $106K in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • KBC Group held 1,296 shares of Tarsus Pharmaceuticals worth $82K as of Q2 2026.
  • KBC Group left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1519 holding.
  • KBC Group first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • KBC Group's Tarsus Pharmaceuticals position peaked at $106K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.